SCHEDULE 13G/A: mDR Limited Amends Beneficial Ownership in CytoMed Therapeutics, Retaining 11.33% Stake
Beneficial Ownership Report
mDR Limited has filed an amendment to its Schedule 13G, disclosing a beneficial ownership of 11.33% in CytoMed Therapeutics Ltd, following a minor share sale.
Summary
- mDR Limited beneficially owns 1,307,933 Ordinary Shares of CytoMed Therapeutics Ltd.
- This ownership represents 11.33% of CytoMed Therapeutics Ltd's outstanding Ordinary Shares, based on 11,540,000 shares outstanding as of April 22, 2024.
- The shares were primarily acquired through two methods: 747,414 Ordinary Shares via subscription between 2021 and 2022 for approximately $1,185,449, and 589,509 Ordinary Shares through the conversion of a convertible loan in April 2023.
- The convertible loan had a principal amount of approximately $1,118,735.08, and the conversion occurred at an approximate price of $1.89774 per share.
- A minor sale of 28,990 Ordinary Shares occurred between December 16, 2024, and January 6, 2025.
Sentiment
Score: 5
Explanation: The document is a factual regulatory filing (Schedule 13G/A) detailing beneficial ownership. It does not contain information that would significantly alter the sentiment towards the company, as it primarily updates an existing stake with a minor adjustment.
Positives
- mDR Limited maintains a significant equity stake of 11.33% in CytoMed Therapeutics Ltd, indicating continued strategic interest and confidence in the company.
Negatives
- mDR Limited sold a small portion of its holdings, specifically 28,990 Ordinary Shares, between December 16, 2024, and January 6, 2025, which represents a minor reduction in its overall stake.
Future Outlook
The document is a beneficial ownership report and does not contain forward-looking statements or guidance regarding future operations or financial performance.
Industry Context
This filing is a routine disclosure of a significant shareholder's updated ownership stake in a publicly traded company, common in the financial industry for transparency and regulatory compliance. It provides insight into the continued investment by mDR Limited in CytoMed Therapeutics Ltd, a biotechnology company.
Stakeholder Impact
- Shareholders: Provides updated information on a significant institutional holder's stake, offering transparency regarding ownership structure.
- Investors: Offers data points for investment analysis, particularly regarding the stability of major shareholder positions.
Key Dates
| Date | Description |
|---|---|
| 2019-12-10 | Date of the original Convertible Loan Agreement between mDR Limited and CytoMed Therapeutics Pte. Ltd. |
| 2021 | Period during which mDR Limited acquired Ordinary Shares of CytoMed Therapeutics Ltd through subscription. |
| 2021-12-31 | Date of a supplemental agreement to the Convertible Loan Agreement. |
| 2022 | Period during which mDR Limited acquired Ordinary Shares of CytoMed Therapeutics Ltd through subscription. |
| 2022-01-03 | Date of a supplemental agreement to the Convertible Loan Agreement. |
| 2023-01-03 | Date of a supplemental agreement to the Convertible Loan Agreement. |
| 2023-04 | Month when 589,509 Ordinary Shares were issued to mDR Limited pursuant to the conversion of the convertible loan. |
| 2024-04-22 | Date as of which CytoMed Therapeutics Ltd reported 11,540,000 Ordinary Shares outstanding in its Annual Report on Form 20-F. |
| 2024-12-16 | Date of event which requires filing of this statement; also the start date for the period during which 28,990 Ordinary Shares were sold. |
| 2025-01-06 | End date for the period during which 28,990 Ordinary Shares were sold. |
| 2025-03-24 | Date of signature for this Schedule 13G/A filing. |
Keywords
CytoMed Therapeutics, mDR Limited, beneficial ownership, Schedule 13G, equity stake, Ordinary Shares, convertible loan, SEC filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.